163 related articles for article (PubMed ID: 22706104)
1. [The discovery of neuromedin U and its pivotal role in the central regulation of energy homeostasis].
Kirsz K; Zięba DA
Postepy Hig Med Dosw (Online); 2012 Apr; 66():196-203. PubMed ID: 22706104
[TBL] [Abstract][Full Text] [Related]
2. The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2).
Peier A; Kosinski J; Cox-York K; Qian Y; Desai K; Feng Y; Trivedi P; Hastings N; Marsh DJ
Endocrinology; 2009 Jul; 150(7):3101-9. PubMed ID: 19324999
[TBL] [Abstract][Full Text] [Related]
3. Neuromedin U inhibits T-type Ca2+ channel currents and decreases membrane excitability in small dorsal root ganglia neurons in mice.
Wang F; Zhang Y; Jiang X; Zhang Y; Zhang L; Gong S; Liu C; Zhou L; Tao J
Cell Calcium; 2011 Jan; 49(1):12-22. PubMed ID: 21106238
[TBL] [Abstract][Full Text] [Related]
4. Activation of neuromedin U type 1 receptor inhibits L-type Ca2+ channel currents via phosphatidylinositol 3-kinase-dependent protein kinase C epsilon pathway in mouse hippocampal neurons.
Zhang Y; Jiang D; Zhang J; Wang F; Jiang X; Tao J
Cell Signal; 2010 Nov; 22(11):1660-8. PubMed ID: 20599609
[TBL] [Abstract][Full Text] [Related]
5. Effects of peripheral administration of a Neuromedin U receptor 2-selective agonist on food intake and body weight in obese mice.
Kaisho T; Nagai H; Asakawa T; Suzuki N; Fujita H; Matsumiya K; Nishizawa N; Kanematsu-Yamaki Y; Dote K; Sakamoto JI; Asami T; Takekawa S
Int J Obes (Lond); 2017 Dec; 41(12):1790-1797. PubMed ID: 28757640
[TBL] [Abstract][Full Text] [Related]
6. Neuromedin U inhibits food intake partly by inhibiting gastric emptying.
Dalbøge LS; Pedersen SL; Secher T; Holst B; Vrang N; Jelsing J
Peptides; 2015 Jul; 69():56-65. PubMed ID: 25895852
[TBL] [Abstract][Full Text] [Related]
7. Neuromedins NMU and NMS: An Updated Overview of Their Functions.
Malendowicz LK; Rucinski M
Front Endocrinol (Lausanne); 2021; 12():713961. PubMed ID: 34276571
[TBL] [Abstract][Full Text] [Related]
8. Signaling and ligand binding by recombinant neuromedin U receptors: evidence for dual coupling to Galphaq/11 and Galphai and an irreversible ligand-receptor interaction.
Brighton PJ; Szekeres PG; Wise A; Willars GB
Mol Pharmacol; 2004 Dec; 66(6):1544-56. PubMed ID: 15331768
[TBL] [Abstract][Full Text] [Related]
9. Effects of peripherally administered neuromedin U on energy and glucose homeostasis.
Peier AM; Desai K; Hubert J; Du X; Yang L; Qian Y; Kosinski JR; Metzger JM; Pocai A; Nawrocki AR; Langdon RB; Marsh DJ
Endocrinology; 2011 Jul; 152(7):2644-54. PubMed ID: 21586559
[TBL] [Abstract][Full Text] [Related]
10. Discovery and pharmacological characterization of a small-molecule antagonist at neuromedin U receptor NMUR2.
Liu JJ; Payza K; Huang J; Liu R; Chen T; Coupal M; Laird JM; Cao CQ; Butterworth J; Lapointe S; Bayrakdarian M; Trivedi S; Bostwick JR
J Pharmacol Exp Ther; 2009 Jul; 330(1):268-75. PubMed ID: 19369576
[TBL] [Abstract][Full Text] [Related]
11. Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S.
Mitchell JD; Maguire JJ; Davenport AP
Br J Pharmacol; 2009 Sep; 158(1):87-103. PubMed ID: 19519756
[TBL] [Abstract][Full Text] [Related]
12. Neuromedin S increases L-type Ca(2+) channel currents through G(i)α-protein and phospholipase C-dependent novel protein kinase C delta pathway in adult rat ventricular myocytes.
Chen RX; Liu F; Li Y; Liu GA
Cell Physiol Biochem; 2012; 30(3):618-30. PubMed ID: 22832358
[TBL] [Abstract][Full Text] [Related]
13. Characterization of neuromedin U (NMU), neuromedin S (NMS) and their receptors (NMUR1, NMUR2) in chickens.
Wan Y; Zhang J; Fang C; Chen J; Li J; Li J; Wu C; Wang Y
Peptides; 2018 Mar; 101():69-81. PubMed ID: 29288685
[TBL] [Abstract][Full Text] [Related]
14. Cloning and expression patterns of neuromedin U and its receptors in pigs.
Li X; Niu M; Su J; Ma Z; Jin M; Qiao W; Zhang Y; Feng Y; An N; Hou Y; Yang S; Chuan S; Lei Z
Neuropeptides; 2017 Aug; 64():47-60. PubMed ID: 28434792
[TBL] [Abstract][Full Text] [Related]
15. PEGylated neuromedin U-8 shows long-lasting anorectic activity and anti-obesity effect in mice by peripheral administration.
Masuda Y; Kumano S; Noguchi J; Sakamoto K; Inooka H; Ohtaki T
Peptides; 2017 Aug; 94():99-105. PubMed ID: 28400225
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical behavior of neuromedin U in isolated smooth muscle cells and intact tissue.
Brighton PJ; Wise A; Dass NB; Willars GB
J Pharmacol Exp Ther; 2008 Apr; 325(1):154-64. PubMed ID: 18180374
[TBL] [Abstract][Full Text] [Related]
17. A PEGylated analog of short-length Neuromedin U with potent anorectic and anti-obesity effects.
Inooka H; Sakamoto K; Shinohara T; Masuda Y; Terada M; Kumano S; Yokoyama K; Noguchi J; Nishizawa N; Kamiguchi H; Fujita H; Asami T; Takekawa S; Ohtaki T
Bioorg Med Chem; 2017 Apr; 25(8):2307-2312. PubMed ID: 28291683
[TBL] [Abstract][Full Text] [Related]
18. Structural insights into the peptide selectivity and activation of human neuromedin U receptors.
You C; Zhang Y; Xu P; Huang S; Yin W; Eric Xu H; Jiang Y
Nat Commun; 2022 Apr; 13(1):2045. PubMed ID: 35440625
[TBL] [Abstract][Full Text] [Related]
19. Neuromedin U receptor 2 knockdown in the paraventricular nucleus modifies behavioral responses to obesogenic high-fat food and leads to increased body weight.
Benzon CR; Johnson SB; McCue DL; Li D; Green TA; Hommel JD
Neuroscience; 2014 Jan; 258():270-9. PubMed ID: 24269937
[TBL] [Abstract][Full Text] [Related]
20. Neuromedin U uses Gαi2 and Gαo to suppress glucose-stimulated Ca2+ signaling and insulin secretion in pancreatic β cells.
Zhang W; Sakoda H; Nakazato Y; Islam MN; Pattou F; Kerr-Conte J; Nakazato M
PLoS One; 2021; 16(4):e0250232. PubMed ID: 33857254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
